UTI Treatments: A Complete NP Board Exam Guide
Last updated: June 2026 — Reviewed by Shaira Cohen, MSN, APRN, FNP-C, CNE
UTI treatments are among the most frequently tested topics on the AANP and ANCC board exams — not because the drugs are complicated, but because getting the right answer requires classifying the infection first. Prescribe nitrofurantoin for pyelonephritis and your patient fails to improve. Use a fluoroquinolone for uncomplicated cystitis and you've walked into one of the exam's favorite trap answers.
This guide organizes UTI treatment the way the boards test it: by infection type, with the dosing rules, pregnancy exceptions, and clinical decision points examiners rely on.
How to Classify a UTI: The Essential First Step
Every antibiotic choice flows from a single upstream decision: what kind of UTI is this? The boards test whether you know the categories before they test whether you know the drugs.
- Uncomplicated UTI (cystitis): Bladder-limited infection in a healthy, non-pregnant, non-elderly woman with a structurally normal urinary tract.
- Complicated UTI: Any infection where host factors raise the risk of treatment failure — male sex, pregnancy, structural or functional urinary tract abnormalities, indwelling catheter, immunosuppression, uncontrolled diabetes, or recent urologic instrumentation.
- Pyelonephritis: Ascending infection to the kidney, producing flank pain, fever, and often nausea or vomiting. Requires an antibiotic that penetrates renal tissue and the bloodstream.
- Asymptomatic bacteriuria (ASB): Bacteria on urine culture without urinary symptoms. Usually not treated — with two critical exceptions.
The most common causative organism across all categories is Escherichia coli, responsible for roughly 80–85% of community-acquired UTIs.
Key point for boards: A UTI in a man is automatically complicated, regardless of symptoms or severity. Male anatomy and the risk of prostatic involvement mandate a longer treatment course and a lower threshold for urine culture.
| Category | Classic Patient | Key Feature | Board Trap |
|---|---|---|---|
| Uncomplicated cystitis | Healthy, non-pregnant woman | Bladder only, no complicating factors | Choosing a fluoroquinolone first-line |
| Complicated UTI | Male, pregnant, catheterized, diabetic, structural abnormality | Host factor that raises failure risk | Treating a male UTI with a standard 3-day cystitis course |
| Pyelonephritis | Fever + flank pain + dysuria | Kidney involved; needs systemic coverage | Prescribing nitrofurantoin or fosfomycin |
| Asymptomatic bacteriuria | Positive culture, no urinary symptoms | Not treated in most patients | Treating ASB in an elderly or diabetic patient |
Treating Uncomplicated Cystitis: First-Line Antibiotics
For a healthy, non-pregnant woman with acute uncomplicated cystitis, three first-line regimens are recommended by the IDSA. The choice between them depends on local resistance patterns, the patient's recent antibiotic history, and renal function.
Nitrofurantoin: Dosing, Duration, and Limitations
Nitrofurantoin is the most commonly tested first-line agent for uncomplicated cystitis — and the drug with the most exam-able limitations.
Standard regimen: Nitrofurantoin monohydrate/macrocrystals (Macrobid) 100 mg twice daily for 5 days.
Why it works for cystitis: Nitrofurantoin concentrates in the urine and achieves high bladder levels. That is precisely why it works for cystitis and why it fails for pyelonephritis — it does not reach therapeutic concentrations in renal tissue or the bloodstream.
Board-critical limitations — memorize all three:
- Do not use for pyelonephritis (inadequate tissue penetration — this is the #1 tested nitrofurantoin fact)
- Avoid in significant renal impairment (CrCl below ~30 mL/min) — reduced renal excretion lowers urinary drug concentration and increases systemic toxicity risk
- Avoid in the first trimester when alternatives exist, and avoid at or near term (approximately ≥36–38 weeks) due to the risk of neonatal hemolytic anemia
TMP-SMX: Efficacy and the 20% Resistance Rule
Trimethoprim-sulfamethoxazole (TMP-SMX) one double-strength (DS) tablet (160/800 mg) twice daily for 3 days is first-line when resistance rates support it.
Use TMP-SMX only when local E. coli resistance is below 20%. If the patient used TMP-SMX within the past three months, select a different agent regardless of local rates — prior exposure predicts reduced susceptibility.
Pregnancy cautions: Avoid in the first trimester (TMP is a folate antagonist, raising the risk of neural tube defects and cardiovascular anomalies) and near term (risk of neonatal hyperbilirubinemia and kernicterus from bilirubin displacement).
Fosfomycin: The Single-Dose Option
Fosfomycin tromethamine 3 g as a single oral dose is first-line and convenient, but carries a somewhat lower cure rate than nitrofurantoin or TMP-SMX. Like nitrofurantoin, it concentrates in the urine and is not appropriate for pyelonephritis. Fosfomycin is generally considered safe in pregnancy.
Why Fluoroquinolones Are Not First-Line for Cystitis
Fluoroquinolones (ciprofloxacin, levofloxacin) are effective against UTI pathogens but are not recommended first-line for uncomplicated cystitis for two reasons:
- Collateral resistance: Broad use for cystitis drives resistance that undermines their efficacy for more serious infections — pyelonephritis, respiratory, and intra-abdominal infections.
- FDA safety warnings: Black box warnings include tendon rupture, peripheral neuropathy, aortic aneurysm and dissection, and QT prolongation. These serious risks are disproportionate for a self-limited bladder infection.
Reserve fluoroquinolones for pyelonephritis and complicated UTIs where systemic penetration is the entire point.
| Antibiotic | Regimen | Use For | Key Caution |
|---|---|---|---|
| Nitrofurantoin | 100 mg BID × 5 days | Uncomplicated cystitis | Not for pyelonephritis; avoid if CrCl <30 mL/min; avoid 1st trimester and at term |
| TMP-SMX | 1 DS tablet BID × 3 days | Uncomplicated cystitis | Avoid if local resistance >20%; avoid 1st trimester and near term |
| Fosfomycin | 3 g single dose | Uncomplicated cystitis | Lower cure rate; not for pyelonephritis; safe in pregnancy |
| Fluoroquinolone (cipro, levo) | 5–7 days | Pyelonephritis, complicated UTI | Not first-line for cystitis; collateral resistance; FDA black box warnings |
| Beta-lactams (amox-clav, cephalexin) | 3–7 days | Second-line cystitis; first-line in pregnancy | Lower cure rate than preferred agents for cystitis; excellent pregnancy safety profile |
Treating Pyelonephritis: Antibiotic Selection and When to Admit
Pyelonephritis demands an antibiotic that reaches therapeutic concentrations in renal tissue and the bloodstream — ruling out nitrofurantoin and fosfomycin entirely.
Always obtain a urine culture before starting antibiotics in pyelonephritis. Empiric therapy covers the first 48–72 hours, but culture results guide de-escalation or adjustment.
Outpatient Management
For a patient who can tolerate oral intake and does not meet criteria for admission:
- Oral fluoroquinolone — ciprofloxacin 500 mg BID × 7 days, or levofloxacin 750 mg once daily × 5 days — is first-choice when local fluoroquinolone resistance is below ~10%.
- If local resistance is higher, give an initial dose of a long-acting parenteral agent (e.g., IM/IV ceftriaxone 1 g) before transitioning to oral therapy based on culture and sensitivity results.
- TMP-SMX DS twice daily × 14 days is acceptable only when organism susceptibility is confirmed by culture — do not use it empirically when resistance is uncertain.
When to Admit
Hospital admission and IV antibiotics are required when the patient has any of the following:
- Sepsis or hemodynamic instability
- Intractable nausea or vomiting precluding oral intake
- Pregnancy (pyelonephritis in pregnancy is always managed inpatient)
- Immunocompromise
- Failure of outpatient therapy
Key point for boards: Pyelonephritis in pregnancy = admit. Regardless of how stable the patient appears clinically, the risk of preterm labor and maternal sepsis makes inpatient management the standard of care.
| Setting | Preferred Antibiotic | Duration | When to Choose |
|---|---|---|---|
| Outpatient | Ciprofloxacin 500 mg PO BID | 7 days | Local FQ resistance <10%, tolerating PO, clinically stable |
| Outpatient | Levofloxacin 750 mg PO daily | 5 days | Local FQ resistance <10%, tolerating PO, clinically stable |
| Outpatient — high FQ resistance area | IM/IV ceftriaxone × 1 dose, then step down to oral per culture | 14 days total | Local FQ resistance ≥10% |
| Inpatient | IV ceftriaxone, IV ampicillin-sulbactam, IV fluoroquinolone, or IV aminoglycoside — transition to PO once stable | IV until 48–72 h afebrile and tolerating PO; total course 10–14 days | Sepsis, vomiting, pregnancy, immunocompromise, or failed outpatient treatment |
UTI in Pregnancy: Screening, Safety Rules, and the Antibiotic Flip
UTI in pregnancy is one of the most reliably tested subtopics on the boards because the rules change from the general population in two critical ways.
Screen and Treat Asymptomatic Bacteriuria in Pregnancy
In non-pregnant patients, asymptomatic bacteriuria is not treated. In pregnancy, it is screened for and treated. Untreated ASB in pregnancy carries up to a 40% risk of progressing to pyelonephritis, along with elevated risks of preterm labor and low birth weight. The USPSTF recommends urine culture screening at 12–16 weeks gestation or at the first prenatal visit if the visit occurs later.
Antibiotic Safety by Trimester
| Antibiotic | 1st Trimester | 2nd Trimester | Near Term (≥36–38 wks) | Reason for Caution |
|---|---|---|---|---|
| Beta-lactams (amoxicillin, amox-clav, cephalexin) | ✓ Safe | ✓ Safe | ✓ Safe | First-line throughout pregnancy; preferred agents |
| Fosfomycin | ✓ Generally acceptable | ✓ Generally acceptable | ✓ Generally acceptable | Considered safe in pregnancy |
| Nitrofurantoin | ⚠ Avoid when alternatives exist | ✓ Generally acceptable | ✗ Avoid | Near term: risk of neonatal hemolytic anemia |
| TMP-SMX | ✗ Avoid | ✓ Generally acceptable with caution | ✗ Avoid | 1st tri: folate antagonism → NTD risk; near term: kernicterus risk |
| Fluoroquinolones | ✗ Avoid | ✗ Avoid | ✗ Avoid | Potential cartilage effects; avoid throughout pregnancy |
Key point for boards: When a question describes a UTI in a first-trimester pregnant patient, beta-lactams are almost always the correct answer. Nitrofurantoin and TMP-SMX become wrong choices specifically in the first trimester and near term. Fluoroquinolones are wrong throughout pregnancy.
Asymptomatic Bacteriuria: Treat or Observe?
Asymptomatic bacteriuria (ASB) — bacteria on culture without urinary symptoms — is one of the most over-treated findings in primary care, and the boards test whether you know when to hold back.
In most patients: do not treat.
The 2019 IDSA guidelines explicitly recommend against treating ASB in:
- Non-pregnant women
- Diabetic patients
- Elderly patients, including those in long-term care facilities
- Patients with indwelling catheters who are otherwise asymptomatic
Treat ASB only in:
- Pregnant patients — risk of progression to pyelonephritis and preterm labor
- Patients about to undergo a urologic procedure with expected mucosal trauma — risk of bacteremia.
Key point for boards: The two populations where ASB is treated are pregnant patients and pre-procedural urologic patients. Elderly patients in nursing homes and diabetic patients are classic exam distractors designed to make you treat — resist the urge.
Recurrent UTIs: Prophylaxis and Patient Education
Recurrent UTI is defined as ≥ 2 symptomatic UTIs in 6 months or ≥ 3 in 12 months, confirmed by culture. Management starts with behavioral measures, not antibiotics.
Behavioral counseling (first-line discussion): Adequate hydration, post-coital voiding, and avoidance of spermicide-based contraception (spermicides disrupt Lactobacillus-dominant vaginal flora, increasing UTI susceptibility).
Postmenopausal patients: Topical vaginal estrogen is a high-yield board answer for this population. It reduces recurrence rates by restoring vaginal flora and lowering urinary tract epithelial susceptibility — without systemic estrogen effects. When a board question describes a postmenopausal woman with multiple UTIs and asks what reduces recurrence, vaginal estrogen is the answer.
Antibiotic prophylaxis (after shared decision-making, for well-documented recurrences):
- Continuous low-dose prophylaxis: nitrofurantoin 50–100 mg nightly, TMP-SMX one SS tablet (80/400 mg) nightly, or cephalexin 250 mg nightly
- Post-coital prophylaxis: single low-dose antibiotic after intercourse, for coitally timed recurrences
- Self-start therapy: patient initiates a full treatment course at symptom onset, appropriate for well-established patterns with a history of culture-confirmed UTIs
Board-Style Practice Questions
1. A healthy 26-year-old non-pregnant woman presents with 2 days of dysuria, frequency, and urgency. Temperature is 98.6°F and she denies flank pain. Urinalysis shows leukocyte esterase and nitrite positive. Which regimen is most appropriate?
Show Answer
2. A patient at 9 weeks gestation presents with dysuria and cloudy urine. Urinalysis shows pyuria and bacteriuria. She has no fever and no flank pain. Which antibiotic class is most appropriate?
Show Answer
3. A 34-year-old woman presents with fever, right flank pain, and dysuria for 24 hours consistent with pyelonephritis. She is hemodynamically stable, tolerating oral fluids, and not pregnant. Local fluoroquinolone resistance is below 10%. What is the appropriate management?
Show Answer
4. A urine culture from a 74-year-old woman in a long-term care facility grows 100,000 CFU/mL of E. coli. She denies dysuria, urgency, frequency, and pelvic discomfort. She is afebrile. What is the appropriate management?
Show Answer
FAQ
How many days should I take nitrofurantoin for a UTI?
How long does nitrofurantoin take to work on a UTI?
What are the best antibiotics for pyelonephritis?
Which UTI antibiotics are safe during pregnancy?
Should asymptomatic bacteriuria always be treated?
Why can't nitrofurantoin treat pyelonephritis?
Conclusion
The key to UTI treatments on the NP boards is to classify first and prescribe second. Uncomplicated cystitis gets nitrofurantoin for 5 days, TMP-SMX for 3 days, or single-dose fosfomycin — not a fluoroquinolone. Pyelonephritis requires systemic coverage, most often an outpatient fluoroquinolone or inpatient IV ceftriaxone. Every male UTI is complicated. Pregnancy flips the antibiotic defaults toward beta-lactams and makes asymptomatic bacteriuria something you screen for and treat. In most other populations — elderly, diabetic, catheterized — ASB is observed, not treated.
These distinctions appear on the boards as case questions where the wrong answer is made to look plausible. The best defense is a clear clinical framework and consistent timed practice.
Build that framework completely — with full-length lectures, drug-by-drug pharmacology, and more than 400 board-style practice questions across every high-yield domain — in The Full Package NP board prep course. Start today and walk into your AANP or ANCC exam knowing exactly why each answer is right.
Sources:
Uncomplicated Cystitis and Pyelonephritis (UTI). Idsociety.org. Published March 2011. https://www.idsociety.org/practice-guideline/uncomplicated-cystitis-and-pyelonephritis-uti/
Recommendation: Asymptomatic Bacteriuria in Adults: Screening | United States Preventive Services Taskforce. www.uspreventiveservicestaskforce.org. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/asymptomatic-bacteriuria-in-adults-screening
